Seed amplification and neurodegeneration marker trajectories in individuals at risk of prion disease
Brain · 01.06.2023 · 146 (6) · 2570-2583
DOI: 10.1093/brain/awad101 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, online erschienen am 28.03.2023. Verfasst von Tze How Mok und 32 weiteren Autor:innen. Beteiligte Einrichtung: Medical Research Council Prion Unit at University College London, UCL Institute of Prion Diseases, London W1W 7FF, UK. Hauptthemen laut MEDLINE: Prion Diseases, Creutzfeldt-Jakob Syndrome, Prions. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Medical Research Council, UK Medical Research Council.
Abstract (Originalsprache)
Human prion diseases are remarkable for long incubation times followed typically by rapid clinical decline. Seed amplification assays and neurodegeneration biofluid biomarkers are remarkably useful in the clinical phase, but their potential to predict clinical onset in healthy people remains unclear. This is relevant not only to the design of preventive strategies in those at-risk of prion diseases, but more broadly, because prion-like mechanisms are thought to underpin many neurodegenerative disorders. Here, we report the accrual of a longitudinal biofluid resource in patients, controls and healthy people at risk of prion diseases, to which ultrasensitive techniques such as real-time quaking-induced conversion (RT-QuIC) and single molecule array (Simoa) digital immunoassays were applied for preclinical biomarker discovery. We studied 648 CSF and plasma samples, including 16 people who had samples taken when healthy but later developed inherited prion disease (IPD) (‘converters’; range from 9.9 prior to, and 7.4 years after onset). Symptomatic IPD CSF samples were screened by RT-QuIC assay variations, before testing the entire collection of at-risk samples using the most sensitive assay. Glial fibrillary acidic protein (GFAP), neurofilament light (NfL), tau and UCH-L1 levels were measured in plasma and CSF. Second generation (IQ-CSF) RT-QuIC proved 100% sensitive and specific for sporadic Creutzfeldt-Jakob disease (CJD), iatrogenic and familial CJD phenotypes, and subsequently detected seeding activity in four presymptomatic CSF samples from three E200K carriers; one converted in under 2 months while two remain asymptomatic after at least 3 years’ follow-up. A bespoke HuPrP P102L RT-QuIC showed partial sensitivity for P102L disease. No compatible RT-QuIC assay was discovered for classical 6-OPRI, A117V and D178N, and these at-risk samples tested negative with bank vole RT-QuIC. Plasma GFAP and NfL, and CSF NfL levels emerged as proximity markers of neurodegeneration in the typically slow IPDs (e.g. P102L), with significant differences in mean values segregating healthy control from IPD carriers (within 2 years to onset) and symptomatic IPD cohorts; plasma GFAP appears to change before NfL, and before clinical conversion. In conclusion, we show distinct biomarker trajectories in fast and slow IPDs. Specifically, we identify several years of presymptomatic seeding positivity in E200K, a new proximity marker (plasma GFAP) and sequential neurodegenerative marker evolution (plasma GFAP followed by NfL) in slow IPDs. We suggest a new preclinical staging system featuring clinical, seeding and neurodegeneration aspects, for validation with larger prion at-risk cohorts, and with potential application to other neurodegenerative proteopathies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Research Council Prion Unit at University College London, UCL Institute of Prion Diseases, London W1W 7FF, UK.
- NHS National Prion Clinic, National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, Queen Square, London WC1N 3BG, UK.
- Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.
- Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK.
- United Kingdom Dementia Research Institute at University College London, London WC1E 6BT, UK.
- Dementia Research Centre, Department of Neurodegenerative Disease, University College London Queen Square Institute of Neurology, London WC1N 3AR, UK.
ORCID-Profile: Jonathan M Schott, Alexander Gerhard, Mario Masellis, Michael P Lunn, Henrik Zetterberg
Förderung
- Wellcome Trust
- Medical Research Council
- UK Medical Research Council
- MRC Prion Unit
- National Prion Clinic
- National Institute of Health Research’s
- Biomedical Research Centre at University College London Hospitals NHS Foundation Trust
- Alzheimer’s Society, UK
Zitieren
APA
Mok, T. H., Nihat, A., Majbour, N., Sequeira, D., Holm-Mercer, L., Coysh, T., Darwent, L., Batchelor, M., Groveman, B. R., Orr, C. D., Hughson, A. G., Heslegrave, A., Laban, R., Veleva, E., Paterson, R. W., Keshavan, A., Schott, J. M., Swift, I. J., Heller, C., …, & Mead, S. (2023). Seed amplification and neurodegeneration marker trajectories in individuals at risk of prion disease. Brain, 146(6), 2570-2583. https://doi.org/10.1093/brain/awad101
Vancouver
Mok TH, Nihat A, Majbour N, Sequeira D, Holm-Mercer L, Coysh T, et al. Seed amplification and neurodegeneration marker trajectories in individuals at risk of prion disease. Brain. 2023;146(6):2570-2583. doi:10.1093/brain/awad101
BibTeX
@article{Mok2023,
author = {Mok, Tze How and Nihat, Akin and Majbour, Nour and Sequeira, Danielle and Holm-Mercer, Leah and Coysh, Thomas and Darwent, Lee and Batchelor, Mark and Groveman, Bradley R and Orr, Christina D and Hughson, Andrew G and Heslegrave, Amanda and Laban, Rhiannon and Veleva, Elena and Paterson, Ross W and Keshavan, Ashvini and Schott, Jonathan M and Swift, Imogen J and Heller, Carolin and Rohrer, Jonathan D and Gerhard, Alexander and Butler, Christopher and Rowe, James B and Masellis, Mario and Chapman, Miles and Lunn, Michael P and Bieschke, Jan and Jackson, Graham S and Zetterberg, Henrik and Caughey, Byron and Rudge, Peter and Collinge, John and Mead, Simon},
title = {Seed amplification and neurodegeneration marker trajectories in individuals at risk of prion disease},
journal = {Brain},
year = {2023},
volume = {146},
number = {6},
pages = {2570--2583},
doi = {10.1093/brain/awad101}
}
EUVIMED